Clinical importance of the range of detectable variants between the Oncomine Dx target test and a conventional single-gene test for EGFR mutation.

MLA

Sakaguchi, Tadashi, et al. “Clinical Importance of the Range of Detectable Variants between the Oncomine Dx Target Test and a Conventional Single-Gene Test for EGFR Mutation.” Scientific Reports, vol. 13, no. 1, Aug. 2023, p. 13759. EBSCOhost, https://doi.org/10.1038/s41598-023-40271-w.

APA

Sakaguchi, T., Iketani, A., Esumi, S., Esumi, M., Suzuki, Y., Ito, K., Fujiwara, K., Nishii, Y., Katsuta, K., Yasui, H., Taguchi, O., & Hataji, O. (2023). Clinical importance of the range of detectable variants between the Oncomine Dx target test and a conventional single-gene test for EGFR mutation. Scientific Reports, 13(1), 13759. https://doi.org/10.1038/s41598-023-40271-w

Chicago

Sakaguchi, Tadashi, Akemi Iketani, Seiya Esumi, Maki Esumi, Yuta Suzuki, Kentaro Ito, Kentaro Fujiwara, et al. 2023. “Clinical Importance of the Range of Detectable Variants between the Oncomine Dx Target Test and a Conventional Single-Gene Test for EGFR Mutation.” Scientific Reports 13 (1): 13759. doi:10.1038/s41598-023-40271-w.